Table 3.
Univariate and multivariate analysis with relative risk of GI status adjusted for site, size, and IRS‐group for patients with synovial sarcoma
| Univariate analysis | ||||
|---|---|---|---|---|
| Risk factors | 5‐year MFS | P value | 5‐year EFS | P value |
| Age at diagnosis | ||||
| ≤10 years | 94.1 ± 5.7% | 0.21 | 88.5 ± 7.6% | 0.38 |
| ≥11 years | 81.2 ± 6.4% | 78.8 ± 6.6% | ||
| Group risk | ||||
| LR + IR | 100% | 0.01 | 95.5 ± 4.4% | <0.04 |
| HR | 75.3 ± 7.6% | 72.7 ± 7.8% | ||
| IRS group | ||||
| IRS I | 95.5 ± 4.6% | 0.26 | 90.5 ± 6.4% | 0.39 |
| IRS II | 80.8 ± 12.2% | 82.5 ± 11.3% | ||
| IRS III | 78.4 ± 8.6% | 74.3 ± 9.1% | ||
| Tumor size | ||||
| ≤5 cm | 92.9 ± 4.9% | 0.09 | 89.8 ± 5.8% | 0.11 |
| >5 cm | 77.3 ± 8.2% | 73.9 ± 8.5% | ||
| Tumor site | ||||
| Limbs | 89.8 ± 4.8% | 0.13 | 84.8 ± 5.7% | 0.38 |
| Axial/Head and Neck | 73.7 ± 11.3% | 74.3 ± 11.1% | ||
| Genomic index | ||||
| Low | 93.8 ± 4.2% | <0.04 | 93.8 ± 4.2% | <0.006 |
| High | 72.9 ± 9.5% | 64.9 ± 10.1% | ||
| Multivariate analysis | ||||
|---|---|---|---|---|
|
MFS Relative risk CI (0.95) |
P value |
EFS Relative risk CI (0.95) |
P value | |
| GI status | ||||
| =0 | 1.00 | <0.04 | 1.00 | <0.009 |
| >0 | 5.3 [0.95–29.8] | 6.7 [1.3–33.9] | ||
| Site | ||||
| Axial/Head and Neck | 1.0 | 1.0 | ||
| Limbs | 0.3 [0.1–1.5] | 0.6 [0.2–2.6] | ||
| Tumor size | ||||
| <5 cm | 1.0 | 1.0 | ||
| ≥5 cm | 1.3 [0.2–9.2] | 1.5 [0.3–7.1] | ||
| IRS group | ||||
| I | 1.0 | 1.0 | ||
| II | 3 [0.2–42.6] | 2.0 [0.2–16.6] | ||
| III | 2.3 [0.2–25.9] | 1.6 [0.3–9.7] | ||
| Age at diagnosis | ||||
| ≤10 years | 1.0 | 1.0 | ||
| ≥11 years | 3.7 [0.3–42.2] | 2 [0.3–12.4] | ||
OS, overall survivals; EFS, event‐free survival; MFS, metastatic‐free survival; HR, high risk; IR, intermediate risk; LR, low‐risk group; IRS‐I/R0, complete resection; IRS‐II/R1, microscopic residue; IRS‐III/R2, macroscopic residue or biopsy; CI, confidence interval.